A Phase 3 interventional study of Lamivudine and Zidovudine in HIV Infections, sponsored by Glaxo Wellcome. Completed at 22 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.
Sponsored by Glaxo Wellcome (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies testing lamivudine in HIV Infections — 5 open to participants now, 8 under way, 4 of them phase 3. Lamivudine · HIV Infections.
Among the 132 studies testing lamivudine in HIV Infections, this one is the 35th largest by enrollment of the 126 interventional ones that give a count, is one of 50 in phase 3, and was the 1st registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →5 of the 132 studies testing lamivudine in HIV Infections are open now, in 4 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in Romania, South Africa, Uganda
José Antonio Mata Marín · Sites in Mexico
Ages 18–70
Instituto Mexicano del Seguro Social · Sites in Mexico
Ages 18+
José Antonio Mata Marín · Sites in Mexico
Ages 18–70 · Men only
University College, London
Ages 4 wk–14 yrs
By country, each count listing its studies:
Lamivudine: first FDA approval 1995 (EPIVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 28 · Phase 3 51 · Phase 4 29
First in 1996; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 325 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 154 across the 126 interventional studies. Of the 112 that completed or were terminated, 21 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 132 have an industry lead sponsor. The 10 most frequent:
This study is registered under Glaxo Wellcome, one of the names counted as GlaxoSmithKline. Under that name alone:
Glaxo Wellcome is the lead sponsor of 72 studies on the registry; none are open to participants now.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 40th largest by enrollment of the 210 interventional ones that give a count, is one of 65 in phase 3, and was the 1st registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing lamivudine in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07031063Instituto Mexicano del Seguro SocialSafety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 132 studies testing lamivudine in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and efficacy of low and high doses of lamivudine ( 3TC ) in combination with zidovudine ( AZT ) and zalcitabine ( dideoxycytidine; ddC ) in combination with AZT.
PER 02/27/95 AMENDMENT: To evaluate the efficacy and safety of both blinded and open-label combination therapy.
Patients are randomized to one of three treatment arms: low-dose 3TC plus AZT, high-dose 3TC plus AZT, or ddC plus AZT. Treatment continues for 32 weeks, with possible extension to 52 weeks.
PER 02/27/95 AMENDMENT: Patients may continue therapy on AZT and low-dose 3TC on an open-label basis. Open-label therapy continues with follow-up every 8 weeks until intolerable toxicity occurs or study terminates.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have:
Exclusion Criteria
Patients with the following prior conditions are excluded:
Prior Medication:
Excluded:
Required:
Required:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study is completed, as verified in May 1994. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lamivudine